Related references
Note: Only part of the references are listed.Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy A Randomized Clinical Trial
Michela Guglieri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Safety and clinical outcome of tamoxifen in Duchenne Muscular Dystrophy (vol 31, pg 803, 2021)
Reuven Tsabari et al.
NEUROMUSCULAR DISORDERS (2022)
Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates
Foster Birnbaum et al.
NPJ REGENERATIVE MEDICINE (2022)
Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data
Raphael Porcher et al.
EUROPEAN HEART JOURNAL (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy
Hasan Mollanoori et al.
GENES & DISEASES (2021)
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Diane E. Frank et al.
NEUROLOGY (2020)
Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents
Sandrine Herbelet et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
Edward C. Smith et al.
PLOS MEDICINE (2020)
The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle
Emma Rybalka et al.
CELLS (2020)
Teaching an Old Molecule New Tricks: Drug Repositioning for Duchenne Muscular Dystrophy
Libero Vitiello et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial
Sara Nagy et al.
TRIALS (2019)
A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet
Francesco Muntoni et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Effect of Combination L-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy A Randomized Clinical Trial
Patricia Hafner et al.
JAMA NETWORK OPEN (2019)
Repurposing the Selective Oestrogen Receptor Modulator Tamoxifen for the Treatment of Duchenne Muscular Dystrophy
Elinam Gayi et al.
CHIMIA (2018)
Tamoxifen therapy in a murine model of myotubular myopathy
Nika Maani et al.
NATURE COMMUNICATIONS (2018)
Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy
Elinam Gayi et al.
NATURE COMMUNICATIONS (2018)
Progress toward Gene Therapy for Duchenne Muscular Dystrophy
Joel R. Chamberlain et al.
MOLECULAR THERAPY (2017)
Duchenne muscular dystrophy: CRISPR/Cas9 treatment
Jerry R. Mendell et al.
CELL RESEARCH (2016)
Second-generation compound for the modulation of utrophin in the therapy of DMD
Simon Guiraud et al.
HUMAN MOLECULAR GENETICS (2015)
Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, Following Single-and Multiple-Dose Administration to Healthy Male Adult Volunteers
Jon Tinsley et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy
Jerry R. Mendell et al.
MOLECULAR THERAPY (2015)
The Anticancer Drug Tamoxifen Counteracts the Pathology in a Mouse Model of Duchenne Muscular Dystrophy
Olivier M. Dorchies et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Philipp Y. Maximov et al.
CURRENT CLINICAL PHARMACOLOGY (2013)
Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up
Francesca Magri et al.
JOURNAL OF NEUROLOGY (2011)
Long-term Follow-up of Tamoxifen Treatment in Adolescents with Gynecomastia
O. Derman et al.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM (2011)
Improvement of cardiac contractile function by peptide-based inhibition of NF-κB in the utrophin/dystrophin-deficient murine model of muscular dystrophy
Dawn A. Delfin et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Peptide-Based Inhibition of NF-κB Rescues Diaphragm Muscle Contractile Dysfunction in a Murine Model of Duchenne Muscular Dystrophy
Jennifer M. Peterson et al.
MOLECULAR MEDICINE (2011)
Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial
Gunnar M. Buyse et al.
NEUROMUSCULAR DISORDERS (2011)
A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements
Disha Jain et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer
V. Craig Jordan
STEROIDS (2007)
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer
VC Jordan
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome
Jonna Frasor et al.
CANCER RESEARCH (2006)
Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice
S Messina et al.
EXPERIMENTAL NEUROLOGY (2006)
Oestrogen receptor β is present in both muscle fibres and endothelial cells within human skeletal muscle tissue
A Wiik et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2005)
Share Paper
